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Abstract 
3E8 is an antibody that targets Sialyl-Tn, a glycan found exclusively on a subset of 
cancers called adenocarcinomas. This antibody is particularly interesting to the Magliery Lab 
because of its use in radioimmunoguided surgery, a modern cancer-detecting technique that 
allows surgeons to intraoperatively visualize and fully resect diseased tissue. Studies have 
shown that patient outcome is directly correlated to the surgeon’s ability to entirely remove 
the tumor; unfortunately, current full-length antibodies, like 3E8 have long serum lifetimes 
and poor affinity to Siayl-Tn.  
Consequently, we have engineered a smaller version of 3E8 called 3E8.scFv, an 
antibody fragment with a tunable serum half-life and affinity and stability nearly equal to full 
length antibodies. Previous studies have shown that the lifetime of 3E8.scFv can be 
optimized by attaching polyethylene glycol chains (PEGs) to the antibody, but not 
without decreasing its ability to bind to Sialyl-Tn. These PEGs, which react non-specifically 
with surface lysine residues on the fragment, may be responsible for the decrease in affinity 
of 3E8.scFv as they block the binding site. To determine which lysines are potentially 
problematic, variants of 3E8.scFv that contain mutations to selected lysines will be 
engineered. These variants will be characterized and studied using a variety of techniques to 
locate a more stable form of 3E8.scFv that can be non-specifically PEGylated. 
In contrast to non-specific PEGylation at lysines, the specific PEGylation of 
3E8.scFv.Cys (3E8.scFv with a C-terminal cysteine) will be studied. A variety of techniques, 
including gel filtration, surface plasmon resonance, differential scanning fluorimetry, and 
analytical ultracentrifugation will help investigate the biophysical effects of singly 
PEGylating 3E8.scFv.Cys with a PEGs of different shapes and sizes. The ultimate goal of 
iii 
 
this project is to create a stable single chain variable fragment with a completely tunable 
serum half-life by PEGylation (non-specifically or specifically) for use in 
radioimmunoguided surgery and imaging. 
In addition to its use in vivo, 3E8.scFv can be used in pathology labs to help detect 
and diagnose adenocarcinomas. The Magliery lab has engineered a variant of 3E8.scFv 
called 3E8.scFv.FLAG that contains a C-terminal FLAG tag for immunohistochemistry. 
Numerous chemistries involving this antibody will be tested and analyzed to develop a 
sensitive and reliable technique for staining adenocarcinomas.  
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Chapter 1: Introduction 
 
1.1 Radioimmunoguided Surgery (RIGS) 
In light of the 1,658,370 new cancer cases predicted by the American Cancer Society for 
2015, a large focus of cancer research has been on developing surgical techniques to 
effectively remove the entirety of a cancer1. In fact, studies have shown that patient outcome 
is directly correlated to the surgeon’s ability to completely remove the tumor. However, 
using today’s surgical methods, it is oftentimes difficult to differentiate healthy tissues from 
cancerous tissues. 
 Computed tomography (CT) and position emission tomography (PET) have 
traditionally been the most commonly used imaging techniques used for the detection of 
cancers. CT scans use differences in electron density of tissues to differentiate healthy tissue 
from a lesion. In contrast, PET imaging detects areas where the uptake and metabolism of 
glucose is high. A radiopharmaceutical such as 2-[18F] fluoro-2-deoxy-D-glucose (FDG) can 
be detected by a PET scan in a cancer because FDGs have a higher rate of metabolism in 
tumors than in most healthy tissue2. Unfortunately, however, CT scans and PET scans have 
limitations that restrict the sensitivity and specificity of their images. PET scans, for example, 
are problematic because other tissues such as the brain and liver display high glucose 
metabolism similar to tumors. Similarly, small molecules such as FDG are often seen during 
a PET scan in organs of the urinary system where they collect during excretion.  As a result, 
it is difficult to differentiate cancerous tissue from background when there exists healthy 
tissues look identical to cancerous tissue on a PET scan3. To overcome the poor signal-to-
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background ratio of CT and PET images, a group at The Ohio State University, headed by 
Dr. Edward Martin, has developed an alternative to CT and PET scans called 
radioimmunoguided surgery (RIGS) to increase the accuracy of surgical detection and 
removal of cancer4. 
 RIGS is a cancer-detecting technique that utilizes a handheld probe for the detection 
of radioactive labeled (125I-labeled) antibodies that bind specifically to cancerous tissue. The 
labeled antibody is injected into the patient prior to surgery and given sufficient time 
(sometimes several days) in the blood circulation to bind to its target, the cancer, and clear 
from the blood. Then, the handheld probe is used before, during, and after surgery to detect 
any cancerous tissue. This imaging tool is most valuable because it allows surgeons to 
intraoperatively determine the extent of local invasion of a tumor and the presence of 
remaining tumor after resection5. Any residual tumor that exists after initial resections can be 
identified and removed immediately at the time of the operation. The complete removal of a 
tumor in one operation eliminates the need for a second surgery and the concern that any 
residual tumor could proliferate. A comprehensive study by Martin, et al. of 212 patients 
with colorectal cancers (Figure 1) showed that patients who had the complete removal of all 
tissue identified by RIGS (Group A) lived significantly longer than those in whom tumor was 
unable to be removed (Group B and C)2. With an extremely sensitive probe that produces 
low background activity and immediate intraoperative information, RIGS is far superior to 
traditional imaging tools like CT and PET scans. 
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1.2 Anti TAG-72 Antibodies of the Past and Present 
  A fundamental part of the RIGS systems is radioactive-labeled antibodies that bind 
specifically to cancer. The antibodies bind to a disaccharide called Sialyl-Tn, which is found 
in a glycoprotein called tumor-associated glycoprotein 72 (TAG-72)6. This glycoprotein is 
expressed at high levels in the mucin secreted by a variety of mucin-secreting cancers called 
adenocarcinomas, including colorectal, gastric, pancreatic, endometrial, breast, prostate, and 
ovarian, but is not found significantly on normal tissues7-9. Figure 2 illustrates the cell surface 
of an adenocarcinoma where Sialyl-Tn can be found in the mucin. 
 
 
 
 
Figure 1. Survival benefit by RIGS with anti-TAG-72 antibodies2 
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Anti TAG-72 antibodies have proven the excellent potential of the RIGS system since 
it was first introduced in 1986. The first generation antibody designed for RIGS, B72.3, 
targeted a variety of adenocarcinomas but failed to bind to primary tumors or lymph nodes 
effectively7,8. Furthermore, when injected into patients with colorectal carcinoma, B72.3 
elicited an undesirable pharmacokinetic property called the human anti-mouse 
immunoglobulin antibodies (HAMA) response, which results from the formation of immune 
complexes, either antigen-antibody or antibody-antibody complexes. Consequently, these 
complexes prevented effective targeting of the antibody to the antigen and detection of the 
antibody in patients10-12. To improve the binding limitations of B72.3, a second-generation 
antibody with higher affinity than B72.3 called CC49 was developed by the National Cancer 
Institute; however, it too elicited the HAMA response. As a result, a group in Korea headed 
by Sun Ok Yoon engineered a humanized form of CC49 called AKA by grafting only the 
Figure 2. Cell membrane of an adenocarcinoma 
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binding regions of CC49 onto a homologous human germ line. After observing a 2-fold 
lower affinity with AKA compared with CC49, Yoon et al. used random mutagenesis of one 
of the binding domains to engineer a number of variants, the highest affinity variant called 
3E8 showing about 22 fold higher affinity than AKA. In 2005, 3E8 had the highest affinity 
and least number of mouse residues among all variants of B72.3 and CC4913-16. 
As shown in Figure 3, antibodies are large Y-shaped proteins consisting of two 
distinct regions: the constant region (the stem of the Y) and the variable region (the top of the 
Y). Each variable region consists of a heavy chain and a light chain and is responsible for 
binding to a specific antigen17. Due to their large size, full length antibodies like 3E8 have 
long serum half-lives and high normal tissue background. In an effort to engineer a smaller 
version of 3E8 with comparable affinity and stability as 3E8, the Magliery lab constructed a 
single chain variable fragment (scFv) called 3E8.scFv by connecting a heavy chain and a 
light chain of the variable region with a string of amino acids. This scFv has similar binding 
properties as full length 3E8; however, due to its reduced physical size (28 kilodaltons versus 
~200 kilodaltons), 3E8.scFv clears the body much faster than 3E8, reducing its exposure to 
the tumor and thus limiting its use as a method to detect cancers intraoperatively. The 
Magliery lab has investigated the use of a variety of polyethylene glycol chains (PEGs) as a 
way to increase the size of 3E8.scFv and increase its serum half-life (plasma circulation 
time). Ideally, a PEGylated scFv, or a scFv that has been conjugated to one of multiple 
PEGS, will have an optimized serum half-life between that of the scFv and full length 
antibody (IgG), as illustrated in Figure 4. 
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1.3 Modification of 3E8 Using Polyethylene Glycol Chains 
1.3.1 Polyethylene Glycol (PEG) 
Polyethylene glycol is a non-toxic, nonimmunogenic, hydrophilic, water soluble 
polymer that has been approved by the Food and Drug Administration (FDA) for its use in 
biopharmaceuticals. Commercial suppliers such as JenKem in China and Creative 
PEGWorks in the USA chemically synthesize PEGs of a variety of lengths up to 40 kDa and 
shapes, including linear and branched. In the past, PEGs have been synthesized using 
polymerization with broad polydispersity, meaning that they contained a large distribution of 
molecular masses; however, recently, stepwise, organic reactions have been used to narrow 
the molecular weight distribution and produce discrete PEGs with much lower 
heterogeneity18,19. To allow for conjugation to a wide variety of functional groups, PEGs are 
Figure 3. Structure of an antibody and scFv Figure 4. Optimized serum half-life 
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terminated on either end during synthesis with hydroxyl groups and have the general 
structure shown in Figure 520.  
 
 
 
1.3.2 Chemistry of PEGylation 
PEGylation is the covalent attachment of polymer polyethylene glycol to a molecule, 
usually a protein or peptide. As discussed earlier, PEGs are able to react with a variety of 
functional groups, most commonly the amine and thiol groups of amino acids in a protein. 
Lysine, which contains an amine group, is one of the most prevalent amino acids found in 
proteins and is often found on the surface of proteins, making it easily accessible for PEG 
reactions. Since a single protein usually contains more than one lysine, a heterogeneous 
mixture of conjugated molecules is often produced, each molecule differing in the number 
and site of the conjugated PEG chains. For this reason, PEGylation at lysines in often termed 
non-specific or random PEGylation. In order for a PEG to react at a particular function 
group, it is first activated by reacting a particular organic molecule with the hydroxyl group 
of the PEG. Figure 6 illustrates the chemical reaction between a N-hydroxysuccinimide-ester 
(NHS-ester) activated PEG and an amine group20. 
Figure 5. General structure of a PEG 
Figure 6. Chemical reaction of NHS-ester activated PEG and amine group 
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Another commonly PEGylated but less prevalent residue on the surface of proteins is 
free cysteine, which contains a thiol functional group. When a protein does not contain any 
unpaired cysteines for PEGylation, one or more can be genetically engineering into the 
protein to allow for what is called site-specific PEGylation. Recently, there has been a trend 
away from non-specific PEGylation and towards site-specific PEGylation because the latter 
produces a homogenous product containing only singly conjugated material. PEGs to be 
reacted with free cysteines are first activated by maleimide chemistry. The activated PEG is 
then reacted with the thiol group to produce a conjugated cysteine, as shown in Figure 719,20. 
 
 
 
 
1.3.3 Theranostic Uses for PEGylation 
 Since the approval of PEGs in 1990, PEGylation has been widely used to improve a 
number of suboptimal physiochemical and pharmacokinetic properties such as limited 
solubility, proteolytic instability, short serum half-life, and immunogenicity of peptides and 
proteins. In fact, the PEGylation of proteins has been so successful that as many as nine 
different PEGylated products have been approved by the FDA for the treatment of such 
conditions as severe combined immunodeficiency disease (SCID), ocular vascular disease, 
hepatitis C, Crohn’s disease, and rheumatoid arthritis19,22. 
Figure 7. Chemical reaction between maleimide-activated PEG and thiol group 
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Figure 8 provides an illustration of some of the ways in which PEGylation directly 
improves proteins. As described earlier in the discussion of anti-TAG-72 antibodies, 
antibodies have the potential to elicit immunogenic reactions when injected into patients. 
This concern has prompted the use of PEGylation to reduce their toxicity and improve their 
safety during administration. The PEG chains, when conjugated to a protein like an antibody, 
can shield the surface of the antibody from the environment where proteolytic enzymes may 
exist, thereby increasing the stability of the molecule19,21. Additionally, PEGs can improve 
circulating half-lives of conjugated antibodies by increasing the apparent size of the molecule 
to above the size filtered by the kidneys. During circulation, blood passes through a structure 
of the kidneys called the glomerulus, which removes anything below 30 kDa for urinary 
excretion. Anything greater than this size will remain in the blood for a time that can be 
tuned using PEGs of different shapes and lengths21. Furthermore, PEGs can increase the 
solubility of a protein in many solvents due to the presence of both hydrophobic and 
hydrophilic groups on the PEG. Consequently, PEGylated proteins can achieve higher 
concentrations in solution without causing aggregation, which can be important when 
considering dosing options for patients23. With the rapidly growing interest in research and 
development of antibodies as therapeutics, the use of PEGs to enhance the properties of these 
molecules is becoming an equally exciting area of research. 
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1.4 Characterization of PEGylated Proteins 
While it is known how PEGs in general can influence the characteristics of a protein, 
a variety of tools and techniques can be used to study the effects that PEGs of various shapes 
and lengths can have on a particular protein’s biophysical characteristics. In the case of an 
antibody, the study of its thermal stability, affinity to the antigen, size, and shape post 
PEGylation is extremely valuable for its potential as a therapeutic. To measure the 
temperature at which the antibody unfolds, differential scanning fluorimetry (DSF) can be 
used. This technique utilizes a fluorescent dye that binds to the hydrophobic parts of the 
protein, which are most often found within the core of the protein. As the temperature of the 
antibody and dye mixture slowly increases, the antibody unfolds and the dye-associated 
hydrophobic residues are gradually exposed24. Meanwhile, the instrument measures the 
increase in fluorescence, eventually producing the graph shown in Figure 9, which can be 
fitted to determine the melting temperature of the protein24. 
 
 
 
Figure 8. Advantages of PEGylated protein 
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Just as important as an antibody’s stability after PEGylation is its ability to retain 
binding to its antigen. Surface plasmon resonance (SPR) is an optical-based assay that 
measures the kinetics of interactions between two molecules such as an antibody and an 
antigen. First, a gold chip coated in carboxymethylated dextran is immobilized with the 
antigen using a particular type of chemistry dependent on the ligand. Then, the solution of 
antibody is flowed over the chip at a constant rate. Meanwhile, as illustrated in Figure 10, a 
beam of light is projected onto the opposite surface of the chip, and the angle of refraction of 
this light is measured in real time. If binding to the antigen occurs, the refractive index 
changes, causing a change in the angle of refraction. After the antigen reaches saturation, the 
antibody is gradually dissociated from the antigen by flowing buffer over the plate, during 
which the angle of refraction again changes and is measured25. The resulting data is then fit 
using a computer program that calculates association and dissociation rate constants, with the 
ratio of the two yielding the affinity constant26. 
Figure 9. Typical unfolding pattern seen in DSF 
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A variety of tools can be used to determine the shape and size of a PEGylated protein. 
Gel filtration chromatography is a purification technique that uses a porous column to 
separate molecules based on their size. The molecules pass through the column at rates that 
are directly proportional to their size: proteins of smaller molecular weight come off the 
column slower than larger molecules because smaller molecules travel through the beads, 
making their path through the column longer than the larger molecules27. In addition to its 
use for purification, gel filtration can be used to study the sizes of molecules with respect to 
each other, for example the sizes of a protein conjugated to various lengths and shapes of 
PEGs. Also, gel filtration can indicate any aggregation of protein after PEGylation, through 
the formation of dimers, trimers, and higher oligomeric states.  
For a more definitive measurement of size, a technique called analytical 
ultracentrifugation (AUC) can be used to determine the shape and size of molecules in 
solution by centrifuging the sample at high speed and analyzing sedimentation with 
hydrodynamic theory. A detector takes absorbance measurements at known times in order to 
Figure 10. Setup of SPR experiment 
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determine the concentration distribution of the sample. Figure 1128 provides an illustration of 
the setup of a typical AUC experiment. During AUC, samples are characterized in their 
native state, under nondestructive conditions such that they can be recovered for further 
characterization29. 
 
 
 
 
 
 
 
 
 
 
1.5 Preliminary Studies of PEGylated 3E8.scFv 
As mentioned at the end of section 1.2, the Magliery lab in interested in conjugating 
3E8.scFv to various types of PEGs in order study the effects of PEGylation on various 
biophysical and pharmacokinetic characteristics. First, 3E8.scFv was PEGylated non-
specifically (at lysines) with a set of discrete NHS-ester PEGs varying in size and shape. For 
each type of PEG, the reaction with 3E8.scFv was done with low loads of PEG (an average 
Figure 11. Setup of AUC experiment28 
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of about one or two attached PEGs per molecule) and medium loads of PEG (an average of 
about five attached PEGs per molecule). Then, each PEGylated sample was characterized 
using many of the techniques discussed in the previous section including DSF and SPR. 
Figures 12 and 13 show the DSF results for the non-specific PEGylation of 3E8.scFv at low 
and medium loads, respectively. The thicker black line represents unPEGylated 3E8.scFv, 
while the colored lines are of PEGylated samples. Taken together, this data showed that low 
loads of non-specific PEGylation did not seem to affect thermal stability; however, higher 
loads of PEGylation seemed to decrease the melting temperature of the sample.  
 
 
 
 
 
 
 
 
In fact, a similar trend was seen after studying the binding of PEGylated 3E8.scFv to 
TAG-72 using SPR. Figure 14 provides a comparison of the data between low and medium 
loads of PEGylation. At low loads, the dissociation constant (KD) remains relatively close to 
that of unPEGylated 3E8.scFv. However, medium loads of PEGylation dramatically ablated 
binding, supporting the conclusion that medium of loads of PEGylation at surface lysines 
Figure 12. Melting curves of 3E8.scFv 
PEGylated at low loads 
Figure 13. Melting curves of 3E8.scFv 
PEGylated at medium loads 
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decreases the stability and affinity of 3E8.scFv30. It seems possible that there may be specific 
lysines in the protein that when PEGylated greatly affect stability and binding. A focus of 
this thesis is to pinpoint lysines, perhaps near the binding site of the antibody fragment that 
may be responsible for the shift in character seen at higher loads of modification. 
 
 
 
  
 
 
 
To understand the effects of modifying a single residue within 3E8.scFv, a new 
version of 3E8.scFv called 3E8.scFv.Cys was engineered to contain a free cysteine residue at 
the C-terminus of the antibody fragment. This cysteine residue was specifically modified 
with four unique PEGs of different sizes and shape using maleimide chemistry. Similar to the 
characterization of PEGylated 3E8.scFv, the thermal stability and binding of PEGylated 
3E8.scFv.Cys was determined. The DSF data, shown in Figure 15, was difficult to 
understand because a large unfolding curve was much more pronounced in the PEGylated 
samples than in the unPEGylated control (3E8.scFv.Cys). Nonetheless, it appeared that 
PEGylation at cysteine, regardless of the size of the PEG, affected the unfolding pattern of 
the conjugated protein significantly. In terms of the binding of these PEGylated samples to 
Figure 14. Dissociation constants for 3E8.scFv PEGylated at low and medium loads 
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TAG-72, the dissociation constants were unchanged between unPEGylated and PEGylated 
3E8.scFv.Cys, each showing slightly weaker binding than 3E8.scFv. In addition to stability 
and affinity, aggregation of the PEGylated samples was studied through gel filtration. This 
data showed that each of the samples still existed solely as monomers and no higher order 
oligomeric states were present. PEGylated 3E8.scFv.Cys has a high potential as a cancer 
therapeutic because of its strong affinity to TAG-72 and its certainty with regards to the site 
of PEGylation30. However, further characterization needs to be completed to understand 
additional structural questions such as the way that the PEG interacts with the protein. 
 
 
 
 
 
 
 
 
1.6 3E8.scFv for Immunohistochemical Analysis 
Immunohistochemistry (IHC) is a tool used in pathology laboratories for the 
visualization, diagnosis, and characterization of cancers. More specifically, it can be used to 
distinguish between various types of cancers, help determine the stage of a cancer, and 
identify post-surgical margins (positive, negative, and close)31. Currently, a variety of 
Figure 15. Melting curves of PEGylated 3E8.scFv.cys 
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antibodies, many of which are commonly used together, exist to target certain epitopes on 
cancers. For the diagnosis of adenocarcinomas, antibodies such as B72.3 and CC49 
(mentioned earlier in section 1.2) are used in commercially available kits32. While B72.3 and 
CC49 have shown proof of principle, the Magliery lab would like to use a variant of 
3E8.scFv called 3E8.scFv.FLAG as an alternative for the diagnosis and analysis of cancers 
like adenocarcinomas. 3E8.scFv.FLAG utilizes a C-terminal FLAG tag (sequence: 
DYKDDDDK) for enhanced immunohistochemical staining and is known to bind better to 
TAG-72 than the first and second generation antibodies. Figure 16 (designed by Dr. Brandon 
Sullivan) offers an illustration of the IHC scheme involving 3E8.scFv.FLAG that the 
Magliery lab is currently investigating. First, the primary antibody (3E8.scFv.FLAG) is 
bound to the antigen (in this case a sugar called Sialyl-Tn). Then, the secondary antibody 
(anti-FLAG Biotin conjugate), which is conjugated to multiple biotin molecules, is bound to 
the primary antibody. The tertiary agent (streptavidin HRP conjugate) binds to the secondary 
antibody via the strevtavidin-biotin linkage, the strongest known non-covalent interaction 
between a protein and a ligand. The HRP (horseradish peroxidase) enzyme picture in yellow 
then reacts with its substrate, 3,3’-diaminobenzidine (DAB) to produce a brown precipitate 
that is easily visualized. Figure 17 shows a section of an adenocarcinoma stained by Kristin 
Miller at the OSU Wexner Medical Center with a biotinylated version of 3E8.scFv that was 
engineered by Dr. Brandon Sullivan. An image like this could be further analyzed by a 
pathologist to identify specific locations of staining within each cell.  
 
 
 
30 
 
 
 
 
 
 
 
Figure 16. IHC scheme of 
3E8.scFv.FLAG with anti-FLAG Biotin 
conjugate 
Figure 17. Adenocarcinoma stained 
with anti-TAG-72 antibody 
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Chapter 2: Objectives 
 
2.1 Identification of and Mutations to PEGylated Lysines 
 Numerous tools will be used in order to locate potentially problematic lysine residues 
that may be responsible for the shift in character of 3E8.scFv at medium amounts of 
modification. Once located, these residues will be systematically replaced with arginine, a 
residue similar in size and structure but that cannot be modified by PEGylation. By 
eliminating possible locations for modification, the goal is to determine which sites are 
problematic, while simultaneously engineering a stable form of 3E8.scFv that can be 
modified at high loads without a dramatic change in biophysical properties.  
2.2 Expression and Purification of 3E8.scFv Constructs 
 The proteins of interest must be produced in enough quantities in order to investigate 
their properties and potential as a tool for Radioimmunoguided surgery. Various versions of 
3E8.scFv will be expressed and purified, including 3E8.scFv (for use in NHS-ester 
PEGylation), 3E8.scFv.Cys (for use in maleimide PEGylation), and 3E8.scFv.FLAG (for use 
in immunohistochemistry). 
2.3 Non-specific PEGylation at Lysines and Characterization 
 After engineering new forms of 3E8.scFv with mutations to specific residues, these 
proteins will be modified by NHS-ester PEGylation. A variety of biophysical techniques can 
be used to study the thermal and kinetic effects of modifying numerous lysines in the 
molecule. The results of these experiments will determine whether the problematic residues 
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were successfully located and if a stable version of 3E8.scFv for non-specific PEGylation 
was engineered. 
2.4 Specific PEGylation at Cysteines and Characterization  
 To study the effects of PEGylation at a single site, 3E8.scFv.Cys will be PEGylated 
using maleimide chemistry. PEGylated 3E8.scFv.Cys can be analyzed using the same tools 
used for NHS-ester PEGylated samples. In addition, its shape and size after PEGylation will 
be studied to potentially understand the PEG’s characteristics once attached to the protein. It 
is possible that PEGs of various sizes and shapes will interact differently with the protein 
after conjugation. 
2.5 Optimization of 3E8.scFv.FLAG for Immunohistochemistry 
 3E8.scFv.FLAG is a mutant of 3E8.scFv that differs only by the addition of a C-
terminal FLAG tag, which is important for immunohistochemistry. The concentrations of 
antigen, primary and secondary antibodies, and development agents will be optimized in 
order to produce a sensitive and reliable in vitro detection method for adenocarcinomas. 
33 
 
Chapter 3: Materials and Methods 
 
3.1 Identification of and Mutations to PEGylated Lysines 
3.1.1 PyMOL 
PyMOL is a molecular graphics software that can be used to produce 3-D images of 
small biological molecules, such as proteins (Schrödinger, Inc.). Using the X-ray crystal 
structure of homologous proteins to 3E8, the program generated a rendering of the protein's 
predicted structure, depicting possible interactions between domains. Of most interest for this 
project was the location of particular lysines residues with respect to the binding domain of 
the protein. 
3.1.2 Mass Spectrometry 
Mass Spectrometry was performed on NHS-ester PEGylated (method described in 
section 3.3.1) 3E8.scFv by Mengxuan Jia in the Wysocki Lab at The Ohio State University. 
The samples were first digested with trypsin in solution at 37 °C for 3 hours. A second 
digestion was performed in gel for one hour at 50 °C. Then, the samples were cleaned using 
C18 solid phase extraction and analyzed by liquid-chromatography mass spectrometry 
(LCMS) using a Velos Pro Dual-Pressure Linear Ion Trap Mass Spectrometer. The location 
and frequency of PEGylated lysines in 3E8.scFv was analyzed by the Proteome Discoverer 
1.4 software. 
3.1.3 Site-Directed Mutagenesis 
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Oligonucleotides containing lysine to arginine point mutations at the 24, 36, 109, 
146/147, 157, 193, 197, and 208 positions of 3E8.scFv were purchased from Sigma-Aldrich. 
With the help of David Alten, a previous undergraduate, the thermodynamic properties of 
these oligonucleotides were optimized using OligoTech. The genes were constructed using 
site-directed mutagenesis PCR, in which the sense and antisense primers anneal to the 
template strand of DNA in two separate reactions, producing two mutagenic fragments. After 
these fragments were annealed together, the reassembled gene was amplified using 
amplification primers that create endonuclease sites within the gene for digestion and 
ligation. Table 1 lists the sequences of the oligonucleotides used to engineer these mutants. 
Each mutagenic primer is bolded where the point mutation was inserted. Amplification 
primers 1 and 2 were used for each variant and designed by graduate student Nick Long. 
Primer Sequence (5'-3') 
K24R GGCGAACGTGCGACGATTAATTGCAGGAGTAGCCAGAGCGTG
CTTTACAGC 
GCTGTAAAGCACGCTCTGGCTACTCCTGCAATTAATCGTCGCA
CGTTCGCC 
K36R AGCGTGCTTTACAGTAGTAACAATAGGAATTACCTGGCGTGGT
ATCAGCAA 
TTGCTGATACCACGCCAGGTAATTCCTATTGTTACTACTGTAAA
GCACGCT 
K109R CCATTGACATTCGGGGGAGGCACCAGAGTGGAGATCAAACTGA
GCGCGG 
CCGCGCTCAGTTTGATCTCCACTCTGGTGCCTCCCCCGAATGTC
AATGG 
K146R, 
K147R 
CTGGTACAGTCGGGTGCGGAAGTGAGGAGACCTGGGGCGTCG
GTGAAAGTGAGC 
GCTCACTTTCACCGACGCCCCAGGTCTCCTCACTTCCGCACCC
GACTGTACCAG 
K157R GGCGTCGGTGAAAGTGAGCTGCAGAGCGAGTGGCTATACCTTT
ACCG 
CGGTAAAGGTATAGCCACTCGCTCTGCAGCTCACTTTCACCGA
CGCC 
K193R CCCCAGGCAACGATGATTTCAGGTATTCACAGAAGTTCCAAGG
GC 
GCCCTTGGAACTTCTGTGAATACCTGAAATCATCGTTGCCTGG
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GG 
K197R AACGATGATTTCAAGTATTCACAGAGGTTCCAAGGGCGCGTGA
CCATTACC 
GGTAATGGTCACGCGCCCTTGGAACCTCTGTGAATACTTGAAA
TCATCGTT 
K208R CGCGTGACCATTACAGCCGATAGAAGTGCAAGCACCGCGTATA
TGG 
CCATATACGCGGTGCTTGCACTTCTATCGGCTGTAATGGTCACG
CG 
Amplification 
1 
ATTATTATTCATATGAAATATCTGTTACCTACTGCTGC 
Amplification 
2 
AATAATGGATCCTTAGCTGCTCACGGTCAC 
 
 
Each amplified gene and pHLIC vector were digested with BamHI and NdeI (NEB). 
The digested gene was ligated into the digested vector using T4 DNA Ligase (NEB) in an 
overnight reaction at 16 °C. The ligation was transformed into DH10B Competent cells, 
recovered with 1 mL of 2YT media, and plated onto an antibiotic plate which was incubated 
overnight at 37 °C. The following day, multiple colonies were picked for overnight growth in 
5 mL of 2YT media with 0.1 g/L antibiotic. The DNA was purified from the cells using the 
Qiagen Miniprep protocol and sequenced at either Genewiz (New Jersey) or Genomics 
Shared Resource (The Ohio State University). 
3.2 Expression and Purification of 3E8.scFv Constructs 
Each of the 3E8.scFv constructs described here (3E8.scFv, 3E8.scFv.Cys, and 
3E8.scFv.FLAG) was expressed and purified using the same conditions. For expression, 1 
µL of miniprep containing the gene of interest inserted into pHLIC vector was transformed 
into C43(DE3) E. coli cells and immediately recovered with 1 mL of media. After incubation 
at 37 °C for 30 minutes, 150 µL were plated on an antibiotic plate using a tertiary streak and 
Table 1. Oligonucleotides used to engineer 3E8.scFv lysine to arginine constructs 
36 
 
incubated overnight at 37 °C. The next day, a seed culture was grown by inoculating 1 
colony from the previous night’s plate into 25 mL of 2YT media containing 1 mM antibiotic 
and 1 mL of 20% glucose. This seed culture was grown overnight at 37 °C and inoculated 
into 1.5 L of 2YT media containing 0.1 g/L antibiotic in a 4L non-baffled flask. The 1.5 L 
culture was grown in a shaker at 37 °C and shaken at 200 rpm until OD600 was in the range of 
0.5-1.0. Then, the culture was cold-shocked by moving it to 4 °C for 30 minutes before 
induction with 0.05 mM IPTG. After incubating the culture for 30 minutes more at 4 °C, it 
was grown overnight at 16 °C in the shaker at 120 rpm. 
The following day, the culture was centrifuged for 10 minutes at 5,000 rpm and 4 °C 
in 1 L centrifuge tubes. The resulting pellet was resuspended in 25 mL of protein L binding 
buffer (56.1 mM Na2HPO4, 144.2 mM NaH2PO4, 150 mM NaCl, pH 7) per liter of culture 
and 5 mM MgCl2, 0.5 mM CaCl2, 5 µL of DNase I and RNase A, 30 mg of lysozyme and 
0.1% Triton X-100. The mixture was allowed to stir on ice for 30 minutes. Then, the cells 
were lysed at 4 °C using the EmulsiFlex (Avestin), which utilizes 3 cycles of high pressure 
(between 15,000 and 20,000 psi) to homogenize the cells. Following lysis, the cell lysate was 
centrifuged for 45 minutes at 15,000 rpm in SS34 tubes. After the first round of 
centrifugation, the supernatant was again centrifuged for 45 minutes at 15,000 rpm. The 
resulting supernatant was collected for affinity chromatography purification using a HiTrap 
Protein L column (GE Healthcare Life Sciences). 
1 mL or 5 mL HiTrap Protein L columns were used for purification depending on the 
size of the cell culture. For each of the steps, a flow rate of 1.0 mL/min (1 mL column) or 5.0 
mL/min (5 mL column) was used. First, the column was washed with 1 column volume (CV) 
of distilled water to remove the storage solution (20% ethanol). Then, the column was 
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equilibrated with 5 CV of protein L binding buffer, and the supernatant was loaded onto the 
column. The column was washed with 10 CV of protein L binding buffer, and the protein 
was eluted with 2 fractions (1 mL column) or 6 fractions (5 mL column) of 5 mL protein L 
elution buffer (100 mM glycine, pH 3). The column was cleaned with 5 CV protein L 
binding buffer, 5 CV 18 MΩ-cm H2O, 5 CV regeneration buffer (6 M Guanidine HCl, 200 
mM HOAC), 5 CV 18 MΩ-cm H2O, and 5 CV 20% ethanol (storage solution). 
The elution fractions containing the protein of interest were pooled together and the 
resulting sample was dialyzed into lysis buffer (50 mM Tris-HCl, 300 mM NaCl, 10 mM 
imidazole, pH 8) with 1 mM TCEP for 3E8.scFv.Cys only. 200 µL of in-house TEV protease 
and 1 mM DTT were added to the sample and allowed to incubate overnight at room 
temperature. The next morning, 100 µL of additional TEV protease and 1 mM DTT were 
added to the sample for incubation until the afternoon, at which point the sample was 
dialyzed into ion exchange buffer A (50 mM potassium acetate, 15 mM NaCl, pH 5) for 
cation exchange chromatography using a 1 mL RESOURCE S column (GE Healthcare Life 
Sciences). 
The 1 mL RESOURCE S column was connected to the ÄKTApurifier FPLC (GE 
Healthcare Life Sciences), washed with 10 CV of 18 MΩ-cm H2O, and equilibrated with 20 
CV of ion exchange buffer A. The sa𝑚ple was loaded onto the column using a Superloop, 
washed with 2 CV of ion exchange buffer A, and eluted from the column using a 200 CV 
gradient (from 15 mM NaCl to 1 M NaCl) with ion exchange buffer B (50 mM potassium 
acetate, 1 M NaCl, pH 5). During the run, the flow rate was increased so much that the 
pressure limit (1.5 MPa) was not exceeded. Furthermore, during the elution phase, the 
gradient was temporarily held when the UV signal quickly rose, indicating the elution of a 
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species from the column. Once the gradient reached 1 M NaCl, the fractions were analyzed 
using gel electrophoresis and any fraction containing the protein of interest were pooled 
together for dialysis into PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM 
KH2PO4, 1 mM TCEP for 3E8.scFv.Cys only) for storage at 4 °C. 
3.3 Non-Specific PEGylation at Lysines and Characterization 
3.3.1 NHS-ester PEGylation 
A protocol by Thermo Scientific was followed for NHS-ester PEGylation of lysines. 
First, the 1.8 kD PEG (Quanta BioDesign) was removed from storage at -20 °C and allowed 
to equilibrate to room temperature before opening. A stock solution of PEG was made by 
dissolving a certain amount of PEG in dimethylformamide (DMF) or dimethyl sulfoxide 
(DMSO). Based upon the desired excess of PEG to protein, the appropriate volume of this 
PEG solution was mixed with 450 µL of the protein, which was stored in PBS, an amine-free 
buffer to prevent NHS-Tris reactions. Calculations were performed to ensure that the total 
amount of organic material (the PEG solution) was kept under 5% to prevent damage to the 
protein's folding. The reaction was brought up to 500 µL with PBS and incubated at room 
temperature for one hour. To quench the reaction, 100x excess of ethanolamine to the amount 
of PEG was added to the reaction. The extent of PEGylation was determined by SDS-PAGE. 
3.3.2 Differential Scanning Fluorimetry (DSF) 
The stock solution of 5000x SYPRO Orange dye (Thermo Scientific) was diluted to 
300x in PBS. To achieve a final concentration of 15x, 1 µL of 300x dye was mixed with 19 
µL of protein (in PBS) in a 96-well 0.2 mL thin-wall PCR plate (USA scientific). The plate 
was sealed with Adhesive PCR Film (Thermo Scientific) after all samples were prepared. All 
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of this was done in the darkest setting to avoid activation of the light-sensitive dye. The 
experiment was performed using a program on a BioRad C1000 Thermal Cycler that 
increases the temperature of the protein solution by 0.2 °C every 12 seconds from 25 °C to 
95 °C and measures the fluorescence at each point. The resulting melting curves were 
normalized and analyzed in Microsoft Excel. 
3.3.3 Surface Plasmon Resonance (SPR) 
Surface Plasmon Resonance was performed in the Plant-Microbe Genomics Facility 
at OSU using a Biacore T100. A CM5 sensor chip (GE Healthcare Life Sciences) was 
immobilized with 0.5 mg/mL BSM (the antigen) and 0.016 mg/mL BSA (the negative 
control) using immobilization buffer (100 mM NaAc, pH 4) and an Amine Coupling kit (1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), N-hydroxysuccinimide 
(NHS), and ethanolamine hydrochloride-NaOH (pH 8.5)). Previous scouting by postdoctoral 
researcher Brandon Sullivan determined that these conditions were most ideal. After washing 
the chip with 50 mM NaOH until a target level of 700 response units was reached, the 
samples were analyzed in HBS buffer (10 mM HEPES, 150 mM NaCl, 3.4 µM EDTA, 
0.005% Tween-20, pH 7.4). In order to accurately study the protein's affinity to the antigen, 
the program suggests preparing a range of concentrations of protein which can be analyzed 
and then fit to a curve. Concentrations of 0, 5, 10, 25, 50, 75, 75, 100, 150, and 200 nM were 
used for each protein. Each of these concentrations was flowed over the chip for 120 seconds 
at a flow rate of 10 µL/minute and dissociation time of 180 seconds. Then, the chip was 
regenerated by flowing regeneration buffer (6 M GuHCl, 200 mM HOAc) over the chip for 
30 seconds at a flow rate of 30 µL/minute and a stabilization period of 0 seconds. Following 
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the completion of all 10 concentrations, the data was fit over all concentrations in the Biacore 
Evaluation software using a 1:1 global fit and a local fit for Rmax, to output a ka, kd, and KD. 
3.4 Specific PEGylation at Cysteines and Characterization 
3.4.1 Maleimide PEGylation 
The procedure used for maleimide PEGylation is similar to that of NHS-ester 
PEGylation. The PEG was removed from -20 °C and allowed to equilibrate to room-
temperature before a stock solution containing a calculated amount of PEG was made in 
PBS. Then, a certain volume of this stock solution was added to the protein solution in PBS 
to achieve the desired excess of PEG to protein. Different from the NHS-ester protocol, the 
PEG solution was added to the protein solution in increments because the PEGs used for 
maleimide PEGylation were much larger and more concentrated than those used for NHS-
ester PEGylation. After combining the two solutions, the reaction was incubated at room 
temperature overnight and quenched the following day by moving it to 4 °C. 5, 20, and 40 
kD PEGs used for this experiment were purchased from JenKem Technologies, USA. 
3.4.2 Gel Filtration 
A 25 mL Superdex 75 10/300 GL size exclusion chromatography column (GE 
Healthcare Life Sciences) was connected to the same ÄKTApurifier FPLC described in 
section 3.2. The column was washed with 2 CV of 18 MΩ-cm H2O and equilibrated with 2 
CV gel filtration buffer (50 mM Tris, 100 mM NaCl, pH 8.0). The sample, which was earlier 
dialyzed into gel filtration buffer, was loaded onto the column using a 200 µL loop. Next, the 
column was washed with 25 mL gel filtration buffer using a constant flow rate. 
3.4.3 Differential Scanning Fluorimetry (DSF) 
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The same protocol discussed in section 3.3.2 was used. 
3.4.4. Surface Plasmon Resonance (SPR) 
The same protocol discussed in section 3.3.3 was used. 
3.4.5 Analytical Ultra Centrifugation (AUC) 
Analytical Ultra Centrifugation was performed at The Ohio State University using a 
ProteomeLab XL-A (Beckman Coulter). 500 µL of PEGylated sample in PBS was loaded 
into a cell that sandwiches the sample between two quartz windows. 
3.5 Optimization of 3E8.scFv.FLAG for Immunohistochemistry 
3.5.1 Western Blots 
The protein(s) to be studied were loaded and run on a 12.5% SDS-PAGE gel with 
rainbow marker (GE Amersham). The gel was transferred to nitrocellulose paper (HyBond 
ECL from GE Amersham) at 200 V for 1 hour, 20 minutes in transfer buffer (25 mM Tris 
base, 192 mM glycine, 10% methanol). The membrane was washed three times with PBST 
(PBS with 0.05% Tween-20) with 5 minute incubations on an orbital mixer between washes. 
To block the membrane, it was incubated overnight with 5% bovine serum albumin (BSA) at 
4 °C. The next day, the BSA was washed off with 3 washes of PBST and the primary 
antibody was incubated with the membrane overnight at 4 °C. After 5 washes with PBST, the 
membrane was either developed with a 1:1 mixture of hydrogen peroxide (0.02%) and 1 
mg/mL diaminobenzidine (DAB) in 50 mM Tris buffer (pH 7.2) or incubated with a 
secondary agent for one hour at room temperature, depending on the experiment. Following 
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the application of the secondary agent (if applicable), it was washed off five times with PBST 
and developed with H2O2/DAB. All dilutions were done in PBS buffer. 
3.5.2 Dot Blot 
The antigen (bovine submaxillary mucin, Sigma Aldrich) was spotted using a pipet 
tip onto the pencil marked corner of a nitrocellulose square. The membrane was incubated at 
room temperature for one hour before being blocked with 10 mg/mL BSA overnight. The 
next day, the BSA was washed off 3 times with PBST, with 5 minute incubations between 
washes on an orbital mixer. The primary antibody was incubated with the membrane for 1.5 
hours and then washed off 3 times with PBST. Next, the secondary antibody was incubated 
with the membrane at room temperature for 1 hour. After 5 washes with PBST, the 
membrane was either developed with H2O2/DAB or incubated with the tertiary agent for 2 
hours at room temperature, similar to the procedure for western blots. If a tertiary agent was 
used, it was washed off five times before development. All dilutions were performed in PBS 
buffer.   
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Chapter 4: Results and Discussion 
 
4.1 Identification and Mutations to PEGylated Lysines 
4.1.1 PyMOL and Mass Spectrometry 
Figure 18 shows a 3-D molecular prediction of the structure of 3E8.scFv. The 
residues represented by spheres are surface-exposed lysines that have the potential to react 
with NHS-ester activated PEGs. During our initial examination of this structure, we located 
five lysines (24, 36, 157, 193, 208) that were located either within or near the binding sites, 
indicated by purple in figure 18. We hypothesized that these residues could be responsible 
for the loss of binding of the protein after higher loads of PEGylation if the PEGs were to 
interact with the binding sites and block the interface from binding to the antigen. 
Figure 18. PyMOL rendering of 3E8.scFv with lysines highlighted 
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To further understand the frequency and location of NHS-ester PEGylation within 
3E8.scFv, NHS-ester PEGylated 3E8.scFv was sent to the Wysocki Lab at The Ohio State 
University for analysis by liquid-chromatography mass spectrometry (LCMS). Figure 19 
shows an SDS-PAGE gel of 3E8.scFv PEGylated with a 1.8 kD discrete PEG (Quanta 
BioDesign) at molar excesses of PEG to protein ranging from 6x to 20x. As shown, the 
number of PEGylated lysines within 3E8.scFv increases as the molar excess of PEG to 
protein increases. The mass spectrometry results showed that there were 9 PEGylated lysines 
between these samples: 36, 109, 146, 147, 193, 197, 208, and 2 residues within the linker 
(not shown in the PyMOL image). To summarize, the blue, orange, and red spheres in figure 
18 are lysine residues identified as potentially problematic by the Magliery lab, by both the 
Magliery lab and the Wysocki Lab, and by only the Wyocki Lab, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.2 Site-Directed Mutagenesis 
Figure 19. NHS-ester PEGylation of 3E8.scFv with 1.8 kD discrete PEG 
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 In order to determine which lysine(s) is problematic, selected lysines in 3E8.scFv 
were systematically mutated to arginines, effectively eliminating PEGylation sites. Before 
PEGylated 3E8.scFv was sent for analysis by mass spectrometry, 5 mutants of 3E8.scFv, 
each containing a lysine replacement were engineered by site-directed mutagenesis: K24R, 
K36R, K157R, K193R, and K208R. Following mass spectrometry, 3 additional mutants of 
3E8.scFv were engineered: K109R, K146/147R, and K197R. The amplified reassembly of 
the mutagenic fragments for each construct (shown in figure 20) was digested and ligated 
into the pHLIC plasmid, which was transformed into DH10B Competent cells. The DNA 
was purified from the cells after an overnight growth and sequence confirmed. 
 
 In order to study the possibility of more than lysine being problematic for PEGylation 
at medium loads, two additional constructs were engineered. A mutant of 3E8.scFv called 
“penta 205C” was synthesized by Genewiz, Inc. (New Jersey, USA) that contained 5 lysine 
to arginine mutations (24, 36, 157, 193, and 208) and the 205C linker that is found in wild-
Figure 20. Amplified gene products for lysine to arginine constructs 
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type 3E8.scFv. Furthermore, the mass spectrometry results indicated that 2 lysines within the 
205C linker were also frequently PEGylated. A second construct, called “penta (G4S)4” was 
synthesized to address this issue. Penta (G4S)4 contains the same 5 mutations as penta 205C, 
in addition to the replacement of the 205C linker with a linker containing only glycines and 
serines. Once received, the genes were digested out of the pUC57 plasmid and ligated into 
pHLIC. Figure 21 shows multiple analytical digests of penta 205C and penta (G4S)4 with 
BamHI and NdeI. The presence of the ~900 bp band indicates that the ligations of the genes 
into pHLIC were successful.  These genes were sequence confirmed. 
 
 
 
 
 
 
 
4.2 Expression and Purification of 3E8.scFv Constructs 
All of the 3E8.scFv constructs were expressed in the same conditions and purified 
using the same techniques, with the exception of K146/147R, K197R, penta 205C, and penta 
(G4S)4. First, the proteins were expressed in C43(DE3) cells, the cells were lysed, and the 
proteins were purified from the cell lysate using affinity chromatography with the protein L 
column. Then, the histidine-tag was cleaved off using TEV protease, and ion exchange 
Figure 21. Analytical digests of penta 205C and penta (G4S)4 
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chromatography with the Resource S column was used to remove the histidine-tag and TEV 
protease from the cleaved protein. Figures 22-29 show the elution profiles from ion exchange 
for 3E8.scFv (wild-type), K24R, K36R, K157R, K193R, K208R, 3E8.scFv.Cys, and 
3E8.scFv.FLAG. The red line indicates the concentration of ion exchange buffer B. Fractions 
from ion exchange containing the purified protein were combined. K146/147R and K197R 
do not have ion exchange profiles because they were not purified by ion exchange after TEV 
cleavage, but rather by nickel column affinity purification. In these cases, the TEV cleaved 
proteins were collected in the flow-through of the nickel column because they no longer 
contained the histidine tag. Penta 205C and penta (G4S)4 were synthesized without histidine 
tags, so they were not TEV cleaved and thus ion-exchange was not needed. 
 
 
 
 
 
 
 
 
 
 
Figure 22. Ion exchange elution profile for 3E8.scFv 
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Figure 23. Ion exchange elution profile for K24R 
Figure 24. Ion exchange elution profile for K36R 
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Figure 25. Ion exchange elution profile for K157R 
Figure 26. Ion exchange elution profile for K193R 
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Figure 27. Ion exchange elution profile for K208R 
Figure 28. Ion exchange elution profile for 3E8.scFv.cys 
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Figure 30 shows an SDS-PAGE gel of the 3E8.scFv lysine to arginine constructs after 
affinity chromatography purification by the protein L column, TEV cleavage, and ion 
exchange chromatography. Based on the gel, it appears that the expression and purification 
resulted in good yields for all constructs except for 157 and penta 205C. In fact, this same 
result was seen after repeated purifications of these two constructs. Additionally, the smaller 
band that exists in some of the constructs towards the bottom of the gel is believed to be 
proteolysis product. Nonetheless, the samples look relatively pure and contain only a small of 
amount of proteolysis products. The characterization and PEGylation of these constructs will 
be discussed in section 4.3.  (K109R is in the process of production.) 
Figure 29. Ion exchange elution profile for 3E8.scFv.FLAG 
52 
 
 
 
 Figures 31, 32, and 33 show the purifications of 3E8.scFv, 3E8.scFv.FLAG, and 
3E8.scFv.Cys, respectively. All three of these constructs appear to be very pure with small 
amounts of proteolysis product in 3E8.scFv and 3E8.scFv.Cys. 
 
 
 
 
 
 
Figure 30. Lysine to arginine constructs after cytoplasmic purification and TEV cleavage 
Figure 31. 3E8.scFv after cytoplasmic purification and 
TEV cleavage Figure 32. 3E8.scFv.FLAG after 
cytoplasmic purification and TEV 
cleavage 
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4.3 Non-Specific PEGylation at Lysines and Characterization 
The ultimate goal of this project is to create a mutant of 3E8.scFv with equal or better 
binding affinity and stability as 3E8.scFv after PEGylation by NHS-ester chemistry. In order 
to study the effect of the mutation(s) on the biophysical properties of 3E8.scFv, differential 
scanning fluorimetry (DSF) and surface plasmon resonance (SPR) were performed for each 
construct. Figure 34 shows the normalized melting curves obtained from DSF for each of the 
unPEGylated lysine to arginine mutants. The black line represents unPEGylated wild-type 
3E8.scFv(205C). While some of the constructs were slightly destabilized, all of the 
constructs have melting temperatures within about 3 °C of wild-type 3E8.scFv(205C). The 
peak seen consistently around 55 °C for some of the samples is hypothesized to be from 
proteolysis product. 
 
 
Figure 33. Cytoplasmic purification of 3E8.scFv.cys 
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Table 2 shows the dissociation constant (KD) for each of the unPEGylated lysine to 
arginine constructs, which represents the dissociation between the antibody and the anitgen 
(TAG-72). Therefore, a smaller KD indicates tighter binding to the target. Each of the single 
mutants retained its binding, while penta (G4S)4 lost some of its binding and was not further 
characterized. 
 
 
 
Figure 34. Melting curves for unPEGylated lysine to arginine constructs 
Table 2. KD values for unPEGylated lysine to arginine constructs 
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Following the initial characterization of the unPEGylated lysine to arginine mutants, 
each of the single mutants was PEGylated at 16x excess (PEG to protein), the “medium load” 
of PEGylation which ablated binding and decreased thermal stability of 3E8.scFv(205C) in 
the preliminary studies. The non-specific PEGylation of the single mutants with a 1.8 kD 
discrete PEG (Quanta BioDesign) using NHS-ester chemistry is shown in figure 35. Every 
construct except K157R appears to have been successfully PEGylated to about the same 
degree. K157R was most likely PEGylated but is too faint to clearly see on the gel. 
 
 
Each of the PEGylated single mutants was characterized using DSF and SPR, similar 
to the unPEGylated mutants. Figure 36 shows the normalized melting curves obtained from 
DSF for the PEGylated single mutants. Again, the black line represents unPEGylated 
3E8.scFv(205C) for reference. Similar to the results of the preliminary studies, these 
Figure 35. NHS-ester PEGylation of lysine to arginine constructs with 1.8 kD discrete PEG 
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constructs were slightly destabilized after 16x excess PEGylation, with the most stable 
constructs appearing to be K193R, K146/147R, and K36R. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 3 shows the KD values for 4 of the 7 PEGylated single mutants. SPR for 
PEGylated K146/147R, K157R, and K197R is currently in progress. While the binding 
affinity has decreased for each of the constructs shown here, the best binding constructs after 
PEGylation are K24R and K208R. Compared to the >1 µM binding constant for PEGylated 
3E8.scFv, K24R and K208R have greatly improved binding affinity to TAG-72. 
 
 
 
 
Figure 36. Melting curves for NHS-ester PEGylated lysine to arginine constructs 
Table 3. KD values for NHS-ester PEGylated lysine to arginine constructs 
57 
 
4.4 Specific PEGylation at Cysteines and Characterization 
 To study the possibility and effects of PEGylation at a single site in 3E8.scFv, a 
mutant of 3E8.scFv called 3E8.scFv.Cys containing a C-terminal cysteine was PEGylated 
using maleimide chemistry. Three linear PEGs of sizes 5 kD, 20 kD, and 40 kD and one 
branched Y-shaped PEG of size 40 kD were used for this experiment. The difference in 
shape between a linear and branched PEG is shown in Figure 37. 
 
 
Four separate samples of 3E8.scFv.Cys were PEGylated overnight at a 50x molar 
excess of PEG to protein. To remove any non-PEGylated protein and the PEG itself, cation 
exchange chromatography was used. The elution profiles of each of the PEGylated samples 
are shown in figures 38-41. The red line represents the concentration of ion exchange buffer 
B at the time of the elution. Once the elution fractions were analyzed by SDS-PAGE, any 
elutions containing the purified protein were combined and dialyzed into PBS for 
characterization. 
 
 
 
Figure 37. Structures of linear and branched maleimide-activated PEGs 
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Figure 38. Ion exchange elution profile of 5 kD PEGylated 3E8.scFv.Cys 
Figure 39. Ion exchange elution profile of 20 kD PEGylated 3E8.scFv.Cys 
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Figure 40. Ion exchange elution profile of 40 kD L PEGylated 3E8.scFv.Cys 
Figure 41. Ion exchange elution profile of 40 kD Y PEGylated 3E8.scFv.Cys 
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Figure 42 shows an SDS-PAGE gel of the ion-exchange purified PEGylated 
3E8.scFv.Cys samples after dialysis into PBS buffer. Each of the samples looks very pure 
with a small amount of proteolysis product towards the bottom of the gel. 
 
 
 
 
 
 
 
 
 
 
 
 
 Gel filtration was performed on each of these samples, in addition to unPEGylated 
3E8.scFv.Cys. 200 µL of sample was run over a 25 mL Superdex 75 10/300 GL size 
exclusion chromatography column (GE Healthcare Life Sciences) at a constant flow rate. 
The elution profile, shown in figure 43, agrees with what one might expect based solely on 
the sizes of the PEGs. Protein conjugated to a larger PEG elutes from the column faster than 
protein conjugated to a smaller PEG. The results also indicate that each of the samples exists 
solely as monomers. The peak at ~11.70 mL, which exists in every sample except 40 kD Y, 
may be from proteolysis product that was previously mentioned. 
 
Figure 42. Maleimide PEGylated 3E8.scFv.cys samples after ion exchange purification 
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 The melting curves obtained from DSF for the PEGylated 3E8.scFv.Cys samples are 
shown in figure 44. The black line represents 3E8.scFv(205C) for comparison, while the 
colored lines indicate 3E8.scFv.Cys and the PEGylated samples. These results show not only 
that 3E8.scFv.Cys has an extremely similar melting point as 3E8.scFv(205C) but also that 
3E8.scFv.Cys is not destabilized by maleimide-activated conjugated to both small and large 
PEGs. The smaller peak at ~52 °C may be of proteolysis product. 
 
 
 
Figure 43. Gel filtration elution profiles of PEGylated 3E8.scFv.Cys samples 
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 The binding affinity of each sample to TAG-72 was analyzed by SPR, the results of 
which are shown in table 4. 3E8.scFv.Cys has slightly decreased binding compared to 
3E8.scFv(205C) but appears to retain its binding after maleimide PEGylation. Also, 
conjugation to larger PEGs seems to disrupt binding slightly more than smaller PEGs. 
 
 
 
 
 
Figure 44. Melting curves of PEGylated 3E8.scFv.Cys samples 
Table 4. KD values for Maleimide PEGylated 3E8.scFv.Cys constructs 
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4.5 Optimization of 3E8.scFv.FLAG for Immunohistochemistry 
 To first determine whether 3E8.scFv.FLAG binds to TAG-72, the scheme illustrated 
in figure 45, which is a simplified version of the one shown in figure 16, was tested using a 
Western blot. After the purification of 3E8.scFv.FLAG, each of the steps of the purification 
was run on a SDS-PAGE gel. The contents of the gel was transferred to a nitrocellulose 
membrane, which was stained with a 1:1000 dilution of anti-FLAG HRP conjugate (Sigma 
Aldrich) overnight and DAB/H2O2. The results, shown in figure 46, indicate that the anti-
FLAG HRP conjugate binds to 3E8.scFv.FLAG, which is found in the 1 µL and 10 µL 
elution lanes. 
  
 
 
 
 
 
 
 
After the success of the western blot, a dot blot was performed using the same 
chemistry. However, this time, bovine submaxillary mucin (which contains TAG-72) was 
first spotted onto the corner of the nitrocellulose. The membrane was incubated with 1 
mg/mL, 0.1 mg/mL, and 0.5 mg/mL 3E8.scFv.FLAG and a 1:5000 dilution of anti-FLAG 
Figure 45. IHC scheme of 
3E8.scFv.FLAG with anti-
FLAG HRP conjugate 
Figure 46. Western blot with anti-FLAG HRP conjugate 
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HRP conjugate for 1 hour, and then developed with DAB/H2O2. A negative control was done 
alongside by replacing 3E8.scFv.FLAG with PBS buffer. The results are shown in figure 47 
and indicate very good staining where the antigen was spotted with almost no background 
staining after the immediate addition of DAB. 
 
 
  
To possibly improve the signal and sensitivity of the staining, an additional step was 
added to the scheme described above. As shown in below in figure 48, the anti-FLAG HRP 
conjugate was replaced with the anti-FLAG Biotin conjugate and a tertiary agent 
(streptavidin HRP conjugate) was added. A Western blot to test this chemistry was 
performed with 3E8.scFv.FLAG, 1:1000 dilution of anti-FLAG biotinylated (Thermo 
Scientific) overnight at 4 °C, VECTASTAIN (Vector Laboratories) for 1 hour at RT, and 
DAB/H2O2. VECTASTAIN was prepared by adding 1 drop of Reagent A and 1 drop of 
Reagent B to 3 mL of PBS buffer. The results are shown in figure 49 and indicate a very 
strong staining for the band of 3E8.scFv.FLAG on the nitrocellulose paper. 
Figure 47. Dot blots with anti-FLAG HRP conjugate 
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The scheme with the anti-FLAG Biotin conjugate and VECTASTAIN was further 
studied with a dot blot. 3E8.scFv.FLAG was spotted onto the corner of nitrocellulose paper 
and developed with a 1:1000 dilution of anti-FLAG Biotin conjugate at RT, VECTASTAIN 
for 2 hours at RT, and DAB/H2O2. Images of the results were not recorded; however, the dot 
blot was as successful as the Western blot shown in figure 49. The blotted corner of 
nitrocellulose stained dark brown with little background staining. 
Figure 49. Western blot with anti-FLAG 
Biotin conjugate and VECTASTAIN 
Figure 48. IHC scheme of 
3E8.scFv.FLAG with anti-FLAG Biotin 
conjugate 
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Chapter 5: Conclusions and Future Directions 
 
Mass spectrometry of non-specifically PEGylated 3E8.scFv showed that many 
surface lysines within the protein were PEGylated. To pinpoint which lysines were 
potentially problematic to binding affinity and stability, these lysines were systematically 
mutated to arginines, thus creating numerous variants of 3E8.scFv. With the exception of two 
variants (K157R and penta 205C), each variant was expressed and purified to give produce 
great yields. These variants were characterized before PEGylation and it was determined that 
the variants containing only a single lysine to arginine mutation retained their binding 
affinity to TAG-72 and were only slightly destabilized. Following non-specific PEGylation, 
the melting curves of the PEGylated samples showed that they were again destabilized, with 
some constructs showing larger destabilization than others. More interestingly, two of the 
constructs (K24R and K208R) retained their binding affinity after PEGylation, thereby 
indicating that the 24 and 208 lysines may be responsible for the ablation of binding seen 
after the PEGylation of wild-type 3E8.scFv. Further analysis of the binding affinity of 
K109R, K146/147R, and K197R may determine if these residues are also problematic for 
non-specific PEGylation. It is possible that the most stable and best binding version of non-
specifically PEGylated 3E8.scFv will have multiple lysine to arginine replacements. Thus, it 
would be interesting to engineer and characterize a variant of 3E8.scFv with mutations only 
to the 24 and 208 lysines, for example. 
 The specific PEGylation of 3E8.scFv was investigated via a variant of 3E8.scFv 
called 3E8.scFv.Cys that contains a free cysteine at the C-terminus. In contrast to non-
specific PEGylation in which numerous lysines were modified, specific PEGylation of 
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3E8.scFv.Cys results in the attachment of only one PEG molecule to a cysteine. This protein 
was modified with a 5 kD, 20 kD, 40 kD linear, and 40 kD branched PEG in order to 
comprehensively study the effects of specific PEGylation using molecules of different sizes 
and shapes. Characterization using gel filtration, differential scanning fluorimetry, and 
surface plasmon resonance showed that 3E8.scFv.Cys retained its monomeric state, stability, 
and binding affinity to TAG-72 after modification. Additional techniques such as multi-angle 
light scattering and small-angle X-ray scattering could provide more information on the 
shape of the PEG after conjugation and its interaction with the protein. 
 While PEGylated 3E8.scFv has the potential use as a tool in radioimmunoguided 
surgery, a variant of 3E8.scFv.FLAG was engineered to help pathologists analyze 
adenocarcinomas in vitro. Initial characterization showed that 3E8.scFv.FLAG binds just as 
well if not better to TAG-72 than first and second generation anti-TAG-72 antibodies like 
B72.3 and CC49. A scheme for immunohistochemistry using 3E8.scFv was developed and 
optimized using an anti-FLAG Biotin conjugate and streptavidin-horseradish peroxidase 
conjugate. The high potential of 3E8.scFv.FLAG as a selective and reliable tool for 
histological staining was confirmed using Western and dot blots that showed dark and 
immediate staining of the antigen and little to no background signal. Currently, 
3E8.scFv.FLAG is being tested on human tissue arrays from various types of 
adenocarcinomas in different stages. The Magliery lab hopes that 3E8.scFv and its variants 
will improve the lives of cancer patients by allowing for the early detection and removal of 
tumors via immunohistochemistry and radioimmunoguided surgery, respectively. 
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